Zacks Investment Research upgraded shares of Nexvet Biopharma PLC (NASDAQ:NVET) from a hold rating to a buy rating in a report published on Tuesday morning. Zacks Investment Research currently has $4.50 price objective on the biopharmaceutical company’s stock.

According to Zacks, “NexvetBiopharma plc is a biopharmaceutical company. The company is focused on transforming the therapeutic market for companion animals by developing and commercializing novel biologic therapies. Its product candidate consists of NV-01, is a mAb for the control of pain associated with osteoarthritis in dogs, NV-02, is a mAb for the control of pain associated with degenerative joint disease in cats and NV-08, is a receptor fusion protein for the treatment of chronic inflammatory diseases. NexvetBiopharma plc is headquartered in Blackrock, Ireland. “

Separately, Credit Suisse Group AG reiterated a buy rating and issued a $8.00 price objective on shares of Nexvet Biopharma PLC in a report on Tuesday, August 16th.

Shares of Nexvet Biopharma PLC (NASDAQ:NVET) opened at 4.09 on Tuesday. The firm’s market cap is $47.96 million. The firm has a 50-day moving average price of $4.02 and a 200 day moving average price of $4.27. Nexvet Biopharma PLC has a one year low of $2.61 and a one year high of $5.70.

A hedge fund recently bought a new stake in Nexvet Biopharma PLC stock. Latimer Light Capital L.P. acquired a new stake in Nexvet Biopharma PLC (NASDAQ:NVET) during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm acquired 37,301 shares of the biopharmaceutical company’s stock, valued at approximately $173,000. Nexvet Biopharma PLC makes up about 0.0% of Latimer Light Capital L.P.’s holdings, making the stock its 22nd largest position. Latimer Light Capital L.P. owned about 0.32% of Nexvet Biopharma PLC at the end of the most recent quarter. Institutional investors and hedge funds own 48.73% of the company’s stock.

ILLEGAL ACTIVITY NOTICE: This report was originally posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this report on another site, it was illegally stolen and republished in violation of U.S. & international trademark and copyright law. The legal version of this report can be read at https://www.thecerbatgem.com/2016/11/23/nexvet-biopharma-plc-nvet-upgraded-to-buy-at-zacks-investment-research.html.

About Nexvet Biopharma PLC

Nexvet Biopharma public limited company is a clinical-stage biopharmaceutical company focused on transforming the therapeutic market for companion animals by developing and commercializing species-specific biologics. The Company’s platform technology, which it refers to as PETization, is an algorithmic approach that enables the Company to create monoclonal antibodies (mAbs) a type of biologic, that are designed to be recognized as self or native by an animal’s immune system, a property referred to as 100% species-specificity.

5 Day Chart for NASDAQ:NVET

Receive News & Stock Ratings for Nexvet Biopharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nexvet Biopharma PLC and related stocks with our FREE daily email newsletter.